PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 4:59 AM ET

Sponsor Check › Person

JL
No photo found yet (own website and image search run after this page is viewed)

Jonathan Leff

Named as an officer, director or promoter on SEC Form D filings · CA, NY, CT, CO, WA, MD, Israel (as filed: L3) · Jun 10, 2010 → Jun 26, 2024

13deals (issuers)
$732.7Mreported sold
288investors
25Form D filings
2010–2024years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:21 AM ET · SEC enforcement last checked: Oct 24, 2026, 12:26 AM ET

The short version

Jonathan Leff is listed as a director on 25 SEC Form D filings by 13 issuers between Jun 2010 and Jan 2026. Largest by amount reported sold: Avalyn Pharma Inc. (Seattle, WA — biotechnology — 2020–2023; $189.2M reported sold to 46 investors), ALPINE IMMUNE SCIENCES, INC. (Seattle, WA — biotechnology — 2014; $91M reported sold to 25 investors), Aprecia Pharmaceuticals Co (Langhorne, PA — pharmaceuticals — 2016; $79M reported sold to 20 investors), Mirum Pharmaceuticals, Inc. (Foster City, CA — biotechnology — 2018; $68.5M reported sold to 14 investors), Audentes Therapeutics, Inc. (San Francisco, CA — biotechnology — 2014–2015; $65M reported sold to 27 investors) and 8 more (all listed below).

What this means That is a lot of deals — 13 separate companies raised money with this person listed as director, over about 16 years. Across those companies the filings report $732.7M sold in total.

Listed alongside Cecilia Gonzalo (5 shared filings), Gregory Louis Merril (4 shared filings), Andrew Ferrer (3 shared filings), Asher Rubin (3 shared filings), C. Boyd Clarke (3 shared filings) and 88 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Jonathan. Each name links to their own page.

1 of the issuers belongs to the sponsor group Alpine Immune Sciences (2 issuers, $108M reported sold, 2014–2021).

What this means A sponsor group is one team that sets up a new company for each deal. Alpine Immune Sciences has 2 companies on file and $108M reported sold in total — the group page shows the whole track record in one place.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 1 bankruptcy case matching the name listed in Key records below.

What this means 1 record came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared 25 public filings for Jonathan Leff and found 13 differences: 7 Form Ds were filed more than 15 days after the first sale; 19 offerings have no amendment in the last 12 months and may still be open; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Jonathan Leff has not run yet — it is joining a line of 3,679 names; searches run around the clock at the hosts' allowed rate. Searched so far: 27 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:21 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (checked Oct 24, 2026) · state securities regulators: AZ, CA, DE, TX, WA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases + SEC administrative proceedings (sec.gov index, 1995-09-19 → 2026-10-23) — last checked Oct 24, 2026, 12:26 AM ET.

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states are not covered.

3. Bankruptcies

1 case: 1 closed (disposition not in docket feed)

Jonathan S Leff and Sheila M M Leff closed
United States Bankruptcy Court, N.D. Illinois · No. 02-74163 · Filed Sep 10, 2002 · Closed Jul 30, 2003
Role of Jonathan S Leff and Sheila M M Leff: Debtor · Outcome: Case closed 2003-07-30 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (rare in federal dockets); 6 people with this name in Form D filings; court in IL (not a filing state)
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:21 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

13 differences found between the filings for Jonathan Leff (compared 25 filings on Oct 24, 2026)

Note · Jan 12, 2011 – Apr 1, 2024

7 Form Ds were filed more than 15 days after the first sale

Form D filed 17 days after the first sale — BiomX Inc. · Form D filed 18 days after the first sale — Avalyn Pharma Inc. · Form D filed 60 days after the first sale — Dracen Pharmaceuticals, Inc. · Form D filed 19 days after the first sale — ARS Pharmaceuticals, Inc. · Form D filed 16 days after the first sale — Audentes Therapeutics, Inc. · and 2 more

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Apr 1, 2024 ↗BiomX Inc. — PartnerFacts page ↗Form D · Oct 10, 2023 ↗Avalyn Pharma Inc. — PartnerFacts page ↗
Sources
Note · May 28, 2010 – Jun 26, 2024

19 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — Elion Therapeutics, Inc. (latest filing Jun 26, 2024) · No amendment in the last 12 months on an offering that may still be open — Dracen Pharmaceuticals, Inc. (latest filing Aug 10, 2023) · No amendment in the last 12 months on an offering that may still be open — Adaptive Phage Therapeutics, Inc. (latest filing Jun 9, 2023) · No amendment in the last 12 months on an offering that may still be open — Innervace, Inc. (latest filing Aug 22, 2022) · No amendment in the last 12 months on an offering that may still be open — Dracen Pharmaceuticals, Inc. (latest filing Nov 10, 2021) · and 14 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Jun 26, 2024 ↗Elion Therapeutics, Inc. — PartnerFacts page ↗Form D · Aug 10, 2023 ↗Dracen Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Jun 10, 2010 – Nov 30, 2012

Jonathan Leff is written 2 different ways on the filings

listed as "Jonathan Leff" on 24 filings (from Jun 10, 2010), and "Jonathan S. Leff" on the Nov 30, 2012 filing.

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Jun 10, 2010 ↗Form D · Nov 30, 2012 ↗Jonathan Leff — PartnerFacts page ↗
Sources
Note · Aug 16, 2017 – Nov 1, 2024

Same name, different state: "Jonathan Leff" (MA) is a separate record

This page covers filings where the address state is CA or NY or CT or CO or WA or MD or L3. A separate record, "Jonathan Leff" with address state MA, is listed on 3 filings — most recently by Axonis Therapeutics, Inc. (Nov 1, 2024). Both records have filings in the same period (Aug 16, 2017 to Jun 26, 2024).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Jonathan Leff (MA) — PartnerFacts page ↗Form D · Nov 1, 2024 ↗Axonis Therapeutics, Inc. — PartnerFacts page ↗Jonathan Leff (CA,NY,CT,CO,WA,MD,L3) — this page ↗
Sources
Note · May 15, 2019 – Jun 10, 2020

Same name, different state: "Jonathan Leff" (PA) is a separate record

This page covers filings where the address state is CA or NY or CT or CO or WA or MD or L3. A separate record, "Jonathan Leff" with address state PA, is listed on 5 filings — most recently by Larimar Therapeutics, Inc. (Jun 10, 2020). Both records have filings in the same period (May 15, 2019 to Jun 10, 2020).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Jonathan Leff (PA) — PartnerFacts page ↗Form D · Jun 10, 2020 ↗Larimar Therapeutics, Inc. — PartnerFacts page ↗Jonathan Leff (CA,NY,CT,CO,WA,MD,L3) — this page ↗
Sources
Note · Sep 17, 2015

Same name, different state: "Jonathan Leff" (IL) is a separate record

This page covers filings where the address state is CA or NY or CT or CO or WA or MD or L3. A separate record, "Jonathan Leff" with address state IL, is listed on 1 filing — most recently by AveXis, Inc. (Sep 17, 2015). Both records have filings in the same period (Sep 17, 2015).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Jonathan Leff (IL) — PartnerFacts page ↗Form D · Sep 17, 2015 ↗AveXis, Inc. — PartnerFacts page ↗Jonathan Leff (CA,NY,CT,CO,WA,MD,L3) — this page ↗
Sources
Note · Mar 4, 2015

Same name, different state: "Jonathan S. Leff" (IA) is a separate record

This page covers filings where the address state is CA or NY or CT or CO or WA or MD or L3. A separate record, "Jonathan S. Leff" with address state IA, is listed on 1 filing — most recently by KEMPHARM, INC (Mar 4, 2015). Both records have filings in the same period (Mar 4, 2015).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Jonathan S. Leff (IA) — PartnerFacts page ↗Form D · Mar 4, 2015 ↗KEMPHARM, INC — PartnerFacts page ↗Jonathan Leff (CA,NY,CT,CO,WA,MD,L3) — this page ↗
Sources
Note · Nov 17, 2008

Same name, different state: "Jonathan S. Leff" (WA) is a separate record

This page covers filings where the address state is CA or NY or CT or CO or WA or MD or L3. A separate record, "Jonathan S. Leff" with address state WA, is listed on 1 filing — most recently by ZYMOGENETICS INC (Nov 17, 2008). The two records do not overlap in time: this page runs Jun 10, 2010 to Jun 26, 2024; the other has one filing dated Nov 17, 2008.

What this means Could be the same person who moved, or two people with the same name. We keep them apart until a filing ties them together. Check both pages before you decide.

Jonathan S. Leff (WA) — PartnerFacts page ↗Form D · Nov 17, 2008 ↗ZYMOGENETICS INC — PartnerFacts page ↗Jonathan Leff (CA,NY,CT,CO,WA,MD,L3) — this page ↗
Sources
Note · Nov 10, 2021 – Aug 10, 2023

Address moved from New York, NY to San Diego, CA — Dracen Pharmaceuticals, Inc.

The people listed on the Nov 10, 2021 filing give New York, NY; on the Aug 10, 2023 filing they give San Diego, CA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Nov 10, 2021 ↗Form D · Aug 10, 2023 ↗Dracen Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Jan 24, 2018 – Nov 10, 2021

Address moved from Baltimore, MD to New York, NY — Dracen Pharmaceuticals, Inc.

The people listed on the Jan 24, 2018 filing give Baltimore, MD; on the Nov 10, 2021 filing they give New York, NY.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Jan 24, 2018 ↗Form D · Nov 10, 2021 ↗Dracen Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Jun 18, 2010 – Jan 13, 2012

Address moved from South San Francisco, CA to San Mateo, CA — Talon Therapeutics, Inc.

The people listed on the Jun 18, 2010 filing give South San Francisco, CA; on the Jan 13, 2012 filing they give San Mateo, CA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Jun 18, 2010 ↗Form D · Jan 13, 2012 ↗Talon Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Jun 10, 2010 – Jan 20, 2026

Jonathan Leff is listed with 7 different address states: NY, CA, CT, CO, WA, MD, L3

NY on 8 filings (Jun 10, 2010 to Jun 26, 2024); CA on 8 filings (Jun 18, 2010 to Aug 10, 2023); CT on 2 filings (Jan 28, 2011 to Nov 30, 2012); CO on 1 filing (Nov 25, 2014); WA on 2 filings (May 8, 2020 to Oct 10, 2023); MD on 2 filings (May 20, 2021 to Jun 9, 2023); Israel (as filed: L3) on 2 filings (Apr 1, 2024 to Jan 20, 2026).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D · Jun 10, 2010 ↗Form D · Jun 18, 2010 ↗Form D · Jan 28, 2011 ↗Form D · Nov 25, 2014 ↗
Sources
Note · Apr 1, 2024 – Jan 20, 2026

Reported revenue range changed between filings — BiomX Inc.

"No Revenues" (Apr 1, 2024); then "Decline to Disclose" (Jan 20, 2026).

What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.

Form D · Apr 1, 2024 ↗Form D · Jan 20, 2026 ↗BiomX Inc. — PartnerFacts page ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

5 of 25 offerings report sales commissions totalling $5,360,759; 1 reports finder's fees totalling $845,624; 1 reports proceeds to related persons totalling $45,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Jan 20, 2026 D
BiomX Inc.
File 021-570448
$210,000$0$0H.C. Wainwright & Co., LLC BrokerCheck CRD 000000375 ↗EDGAR ↗
Jun 26, 2024 D
Elion Therapeutics, Inc.
File 021-516941
$0$0$0 (est.)None listed on this filingEDGAR ↗
Apr 1, 2024 D
BiomX Inc.
File 021-509186
$1,381,852$0$0Laidlaw & Company (UK) Ltd. BrokerCheck CRD 119037 ↗
RBC Capital Markets, LLC BrokerCheck CRD 31194 ↗		EDGAR ↗
Oct 10, 2023 D
Avalyn Pharma Inc.
File 021-494182
$0$0$0None listed on this filingEDGAR ↗
Aug 10, 2023 D
Dracen Pharmaceuticals, Inc.
File 021-489348
$0$0$45,000 (est.)None listed on this filingEDGAR ↗
Jun 9, 2023 D
Adaptive Phage Therapeutics, Inc.
File 021-483867
$0$0$0None listed on this filingEDGAR ↗
Aug 22, 2022 D
Innervace, Inc.
File 021-456567
$0$0$0None listed on this filingEDGAR ↗
Nov 10, 2021 D
Dracen Pharmaceuticals, Inc.
File 021-420647
$0$0$0None listed on this filingEDGAR ↗
Sep 7, 2021 D
ARS Pharmaceuticals, Inc.
File 021-412547
$0$0$0None listed on this filingEDGAR ↗
May 20, 2021 D
Adaptive Phage Therapeutics, Inc.
File 021-400058
$0$0$0None listed on this filingEDGAR ↗
May 8, 2020 D
Avalyn Pharma Inc.
File 021-366535
$0$0$0None listed on this filingEDGAR ↗
Nov 20, 2018 D
Mirum Pharmaceuticals, Inc.
File 021-326260
$0$0$0None listed on this filingEDGAR ↗
Oct 3, 2018 D
ARS Pharmaceuticals, Inc.
File 021-322748
$0$0$0None listed on this filingEDGAR ↗
Jan 24, 2018 D
Dracen Pharmaceuticals, Inc.
File 021-303962
$0$0$0None listed on this filingEDGAR ↗
Jan 28, 2016 D
Aprecia Pharmaceuticals Co
File 021-256143
$3,168,907$0$0MTS Securities, LLC BrokerCheck CRD 104059 ↗EDGAR ↗
Oct 22, 2015 D
Audentes Therapeutics, Inc.
File 021-249874
$0$0$0None listed on this filingEDGAR ↗
Sep 2, 2015 D
Audentes Therapeutics, Inc.
File 021-246838
$0$0$0None listed on this filingEDGAR ↗
Dec 24, 2014 D
Audentes Therapeutics, Inc.
File 021-230835
$0$0$0None listed on this filingEDGAR ↗
Nov 25, 2014 D
ALPINE IMMUNE SCIENCES, INC.
File 021-228991
$0$845,624$0None listed on this filingEDGAR ↗
Nov 30, 2012 D
Rib-X Pharmaceuticals, Inc.
File 021-187690
$0$0$0 (est.)None listed on this filingEDGAR ↗
Jan 13, 2012 D
Talon Therapeutics, Inc.
File 021-171877
$0$0$0None listed on this filingEDGAR ↗
Jan 13, 2012 D
Talon Therapeutics, Inc.
File 021-171878
$200,000 (est.)$0$0Roth Capital Partners, LLC BrokerCheck CRD 15407 ↗
via Roth Capital Partners, LLC (CRD 15407 ↗)
EDGAR ↗
Jan 28, 2011 D
Rib-X Pharmaceuticals, Inc.
File 021-154520
$0$0$0 (est.)None listed on this filingEDGAR ↗
Jun 18, 2010 D
Talon Therapeutics, Inc.
File 021-143754
$400,000 (est.)$0$0Roth Capital Partners, LLC BrokerCheck CRD 15407 ↗
via Roth Capital Partners, LLC (CRD 15407 ↗)
EDGAR ↗
Jun 10, 2010 D
Rib-X Pharmaceuticals, Inc.
File 021-143283
$0$0$0 (est.)None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 13

Every issuer that named Jonathan Leff on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

B
Pharmaceuticals

BiomX Inc.

Ness Ziona, Israel (as filed: L3) · Apr 1, 2024 → Jan 20, 2026 · 2 filings
  • Jan 20, 2026 · D · $3,300,000 sold of $3,300,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 1, 2024 · D · $61,547,439 sold of $61,547,439 · 34 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $61.5M from 34 investors (100% of the $3.3M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

ET
Biotechnology

Elion Therapeutics, Inc.

New York, NY · Jun 26, 2024
  • Jun 26, 2024 · D · $25,436,790 sold of $83,835,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $25.4M from 6 investors (30% of the $83.8M target) as of the latest filing. Jonathan is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AP
Biotechnology

Avalyn Pharma Inc.

Seattle, WA · May 8, 2020 → Oct 10, 2023 · 2 filings
  • Oct 10, 2023 · D · $189,182,622 sold of $189,182,622 · 26 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 8, 2020 · D · $35,499,998 sold of $35,695,957 · 8 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $189.2M from 46 investors (100% of the $189.2M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

DP
Biotechnology

Dracen Pharmaceuticals, Inc.

San Diego, CA · Jan 24, 2018 → Aug 10, 2023 · 3 filings
  • Aug 10, 2023 · D · $2,285,000 sold of $2,785,000 · 6 investors · min. $2,741 · role: Director EDGAR ↗
  • Nov 10, 2021 · D · $8,584,398 sold of $17,046,698 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 24, 2018 · D · $8,488,896 sold of $40,489,688 · 9 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $8.58M from 9 investors (100% of the $2.79M target) as of the latest filing. Jonathan is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AP
Biotechnology

Adaptive Phage Therapeutics, Inc.

Gaithersburg, MD · May 20, 2021 → Jun 9, 2023 · 2 filings
  • Jun 9, 2023 · D · $11,999,999 sold of $30,000,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 20, 2021 · D · $23,262,000 sold of $53,262,037 · 59 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $23.3M from 59 investors (78% of the $30M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

I
Biotechnology

Innervace, Inc.

New York, NY · Aug 22, 2022
  • Aug 22, 2022 · D · $9,999,973 sold of $40,000,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $10M from 7 investors (25% of the $40M target) as of the latest filing. Jonathan is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AP
Pharmaceuticals

ARS Pharmaceuticals, Inc.

San Diego, CA · Oct 3, 2018 → Sep 7, 2021 · 2 filings
  • Sep 7, 2021 · D · $54,999,987 sold of $54,999,987 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 3, 2018 · D · $8,000,002 sold of $20,000,003 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $55M from 8 investors (100% of the $55M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

MP
Pharmaceuticals

Mirum Pharmaceuticals, Inc.

Foster City, CA · Nov 20, 2018
  • Nov 20, 2018 · D · $60,063,750 sold of $120,063,750 · 14 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $68.5M from 14 investors (57% of the $120.1M target) as of the latest filing. Jonathan is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AP
Pharmaceuticals

Aprecia Pharmaceuticals Co

Langhorne, PA · Jan 28, 2016
  • Jan 28, 2016 · D · $78,996,852 sold of $83,996,852 · 20 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $79M from 20 investors (94% of the $84M target) as of the latest filing. Jonathan is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AT
Biotechnology

Audentes Therapeutics, Inc.

San Francisco, CA · Dec 24, 2014 → Oct 22, 2015 · 3 filings
  • Oct 22, 2015 · D · $64,999,949 sold of $64,999,949 · 27 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 2, 2015 · D · $0 sold of Indefinite · 21 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 24, 2014 · D · $42,500,002 sold of $42,500,002 · 11 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $65M from 27 investors (100% of the $65M target) as of the latest filing. Jonathan is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AI
Pharmaceuticals · group: Alpine Immune Sciences

ALPINE IMMUNE SCIENCES, INC.

Seattle, WA · Nov 25, 2014
  • Nov 25, 2014 · D · $30,000,000 sold of $40,000,000 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $91M from 25 investors (100% of the $40M target) as of the latest filing. Jonathan is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RX
Pharmaceuticals

Rib-X Pharmaceuticals, Inc.

New Haven, CT · Jun 10, 2010 → Nov 30, 2012 · 3 filings
  • Nov 30, 2012 · D · $18,686,500 sold of $67,500,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 28, 2011 · D · $5,500,000 sold of $22,000,000 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 10, 2010 · D · $5,500,000 sold of $15,000,000 · 16 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $18.7M from 16 investors (28% of the $67.5M target) as of the latest filing. Jonathan is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

TT
Biotechnology

Talon Therapeutics, Inc.

San Mateo, CA · Jun 18, 2010 → Jan 13, 2012 · 3 filings
  • Jan 13, 2012 · D · $10,315,800 sold of $70,390,800 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 13, 2012 · D · $258,000 sold of $2,291,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 18, 2010 · D · $37,512,000 sold of $97,562,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $37.5M from 17 investors (53% of the $70.4M target) as of the latest filing. Jonathan is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other pages with the same name (5)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

  • Jonathan Leff — MA, 3 issuers, Aug 16, 2017 → Nov 1, 2024 · no shared issuer
  • Jonathan Leff — PA, 2 issuers, May 15, 2019 → Jun 10, 2020 · no shared issuer
  • Jonathan S. Leff — IA, 1 issuer, Mar 4, 2015 → Mar 4, 2015 · no shared issuer
  • Jonathan Leff — IL, 1 issuer, Sep 17, 2015 → Sep 17, 2015 · no shared issuer
  • Jonathan S. Leff — WA, 1 issuer, Nov 17, 2008 → Nov 17, 2008 · no shared issuer

People around Jonathan 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

BM
Management entity

Bruce Montgomery

Executive Officer, Director · 1 shared filing (1 issuer) · also on 2 other issuers

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

CG
No photo found yet (own website and image search run after this page is viewed)
Person

Cecilia Gonzalo

Director · 5 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

GM
No photo found yet (own website and image search run after this page is viewed)
Person

Gregory Louis Merril

Executive Officer, Director, Promoter · 4 shared filings (2 issuers)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

MP
No photo found yet (own website and image search run after this page is viewed)
Person

Matthew Patterson

Executive Officer, Director · 3 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

TA
No photo found yet (own website and image search run after this page is viewed)
Person

Tiba Aynechi

Director · 3 shared filings (2 issuers) · also on 9 other issuers

Tiba Aynechi is on 11 issuers in total — a repeat sponsor. Their page lists every one.

JS
No photo found yet (own website and image search run after this page is viewed)
Person

Jonathan T. Silverstein

Director · 3 shared filings (1 issuer) · also on 32 other issuers

Jonathan T. Silverstein is on 33 issuers in total — a repeat sponsor. Their page lists every one.

HP
No photo found yet (own website and image search run after this page is viewed)
Person

Harry H. Penner, Jr.

Director · 3 shared filings (1 issuer) · also on 4 other issuers

Harry H. Penner, Jr. is on 5 issuers in total — a repeat sponsor. Their page lists every one.

PM
No photo found yet (own website and image search run after this page is viewed)
Person

Paul Maier

Director · 3 shared filings (1 issuer) · also on 9 other issuers

Paul Maier is on 10 issuers in total — a repeat sponsor. Their page lists every one.

SD
No photo found yet (own website and image search run after this page is viewed)
Person

Steven R. Deitcher, M.D.

Executive Officer, Director · 3 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

LD
No photo found yet (own website and image search run after this page is viewed)
Person

Leon E. Rosenberg, M.D.

Director · 3 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

HD
No photo found yet (own website and image search run after this page is viewed)
Person

Howard P. Furst, M.D.

Director · 3 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

AF
No photo found yet (own website and image search run after this page is viewed)
Person

Andrew Ferrer

Director · 3 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

ML
No photo found yet (own website and image search run after this page is viewed)
Person

Mark Leuchtenberger

Executive Officer, Director · 3 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

RC
No photo found yet (own website and image search run after this page is viewed)
Person

Robert Conerly

Executive Officer, Director · 3 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

TS
No photo found yet (own website and image search run after this page is viewed)
Person

Thomas Schuetz

Director · 3 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

CC
No photo found yet (own website and image search run after this page is viewed)
Person

C. Boyd Clarke

Director · 3 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

KP
No photo found yet (own website and image search run after this page is viewed)
Person

Kush Parmar

Director · 3 shared filings (1 issuer) · also on 16 other issuers

Kush Parmar is on 17 issuers in total — a repeat sponsor. Their page lists every one.

TW
No photo found yet (own website and image search run after this page is viewed)
Person

Thomas Woiwode

Director · 3 shared filings (1 issuer) · also on 24 other issuers

Thomas Woiwode is on 25 issuers in total — a repeat sponsor. Their page lists every one.

AR
No photo found yet (own website and image search run after this page is viewed)
Person

Asher Rubin

Executive Officer · 3 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

DD
No photo found yet (own website and image search run after this page is viewed)
Person

Drew Pardoll, M.D., Ph.D.

Director · 3 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

EL
No photo found yet (own website and image search run after this page is viewed)
Person

Evan Loh

Director · 3 shared filings (2 issuers)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

JG
No photo found yet (own website and image search run after this page is viewed)
Person

Jesse Goodman

Director · 3 shared filings (2 issuers)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

CC
No photo found yet (own website and image search run after this page is viewed)
Person

Craig W. Carlson

Executive Officer · 3 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

PS
No photo found yet (own website and image search run after this page is viewed)
Person

Pratik Shah

Director · 2 shared filings (1 issuer) · also on 7 other issuers

Pratik Shah is on 8 issuers in total — a repeat sponsor. Their page lists every one.

LL
No photo found yet (own website and image search run after this page is viewed)
Person

Louis Lange

Director · 2 shared filings (1 issuer) · also on 8 other issuers

Louis Lange is on 9 issuers in total — a repeat sponsor. Their page lists every one.

RL
No photo found yet (own website and image search run after this page is viewed)
Person

Richard Lowenthal

Executive Officer, Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

TE
No photo found yet (own website and image search run after this page is viewed)
Person

Thomas M. Estok

Executive Officer, Director · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

RM
No photo found yet (own website and image search run after this page is viewed)
Person

Raymond L. Martz

Director · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

RS
No photo found yet (own website and image search run after this page is viewed)
Person

Robert J. Spiegel

Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

KP
No photo found yet (own website and image search run after this page is viewed)
Person

Ketan Patel

Director · 2 shared filings (1 issuer) · also on 11 other issuers

Ketan Patel is on 12 issuers in total — a repeat sponsor. Their page lists every one.

DB
No photo found yet (own website and image search run after this page is viewed)
Person

Dennis Bilski

Executive Officer · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

SS
No photo found yet (own website and image search run after this page is viewed)
Person

Steve Squinto

Director · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

ND
No photo found yet (own website and image search run after this page is viewed)
Person

Niall O'Donnell

Director · 2 shared filings (1 issuer) · also on 11 other issuers

Niall O'Donnell is on 12 issuers in total — a repeat sponsor. Their page lists every one.

CM
No photo found yet (own website and image search run after this page is viewed)
Person

Carl Merril

Executive Officer, Director · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

JJ
No photo found yet (own website and image search run after this page is viewed)
Person

Jana Jensen

Director · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

JS
No photo found yet (own website and image search run after this page is viewed)
Person

Jonathan Solomon

Executive Officer, Director · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

RG
No photo found yet (own website and image search run after this page is viewed)
Person

Russell Greig

Director · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

MW
No photo found yet (own website and image search run after this page is viewed)
Person

Marina Wolfson

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

MB
No photo found yet (own website and image search run after this page is viewed)
Person

Merav Bassan

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

AM
No photo found yet (own website and image search run after this page is viewed)
Person

Alan Moses

Director · 2 shared filings (1 issuer)

Listed on the same filings as Jonathan Leff. Their page shows their other deals.

The team behind the deals

AI
Sponsor group

Alpine Immune Sciences

2 issuers · 8 filings · $108M reported sold · 2014–2021

One team, 2 deal companies. Jonathan Leff is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Jonathan Leff.

Same business address

51 other issuers file from the same address (first 50 shown)

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Adviser registration (Form ADV)

None of the 13 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Jonathan Leff by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 13 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Jonathan Leff is listed on: none on file. No website or social profile named in Aprecia Pharmaceuticals Co's SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #293,021 of 374,652 in line (14 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Langhorne, PA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗California — find the county court ↗Los Angeles Superior Court case search ↗New York WebCivil Supreme ↗Connecticut Judicial Branch case look-up ↗Colorado state courts — find the court ↗Washington Courts case search (dw.courts.wa.gov) ↗Maryland Judiciary case search ↗Pennsylvania UJS portal case search ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

California Secretary of State business search ↗New York Secretary of State business search ↗Connecticut Secretary of State business search ↗Colorado Secretary of State business search ↗Washington Secretary of State business search ↗Maryland Secretary of State business search ↗Pennsylvania Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Jonathan Leff appears on a new Form D, or when a court case or SEC action is matched to them. See plans →